First Eagle Investment Management LLC Takes Position in CryoPort, Inc. $CYRX

First Eagle Investment Management LLC bought a new stake in CryoPort, Inc. (NASDAQ:CYRX) in the fourth quarter, HoldingsChannel reports. The fund bought 312,061 shares of the company’s stock, valued at approximately $2,996,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its position in shares of CryoPort by 285.5% during the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after acquiring an additional 194,482 shares during the last quarter. Creative Planning purchased a new stake in CryoPort in the 2nd quarter valued at $96,000. Rhumbline Advisers boosted its stake in CryoPort by 17.6% during the 2nd quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock worth $687,000 after purchasing an additional 13,778 shares during the period. American Century Companies Inc. grew its position in CryoPort by 24.4% during the 2nd quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock worth $663,000 after purchasing an additional 17,459 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in CryoPort during the 2nd quarter worth $254,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort Stock Up 1.6%

Shares of NASDAQ:CYRX opened at $13.25 on Thursday. The company has a market cap of $667.83 million, a price-to-earnings ratio of 9.81 and a beta of 1.75. The firm’s 50-day simple moving average is $9.56 and its 200-day simple moving average is $9.45. CryoPort, Inc. has a fifty-two week low of $5.31 and a fifty-two week high of $13.79.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The firm had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $44.86 million. CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%. On average, research analysts forecast that CryoPort, Inc. will post -0.74 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $63,344.00. Following the completion of the transaction, the chief executive officer directly owned 1,054,501 shares of the company’s stock, valued at approximately $8,436,008. This represents a 0.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Mark W. Sawicki sold 3,235 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the sale, the insider directly owned 103,697 shares of the company’s stock, valued at $829,576. This represents a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 59,939 shares of company stock worth $471,183. Company insiders own 10.00% of the company’s stock.

Analyst Upgrades and Downgrades

CYRX has been the subject of a number of research reports. Guggenheim upped their target price on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. BTIG Research boosted their price target on CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a research note on Monday. Weiss Ratings upgraded CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Finally, Needham & Company LLC boosted their target price on CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, CryoPort currently has an average rating of “Moderate Buy” and an average price target of $14.44.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.